Presenting author

Wiesław J. Cubała

2 presentations

• W40. Impact of GH001 on depressive symptoms, anxiety, and quality of life in treatment-resistant depression: Results from a phase 2b trial

  2026 ASCP Annual Meeting

• PS02-2130. Inhaled mebufotenin (GH001) is associated with rapid improvement in symptoms of anhedonia in treatment-resistant depression

  2026 ECNP Congress